All In Biotech

Drug Trial Radar · NCT07733856

Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)

Open-Label Early Access Treatment With Intracerebroventricular Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Spruce BiosciencesIndustry
Sponsor type
Industry
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 12 months

Summary

As written by the sponsor on the registry.

This is an intermediate-size patient population Early Access Program (EAP) providing access to intracerebroventricular (ICV) tralesinidase alfa (TA) for participants with mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo Syndrome Type B). The primary objectives are to allow early access to TA treatment and to evaluate the safety and tolerability of TA ICV infusion. Approximately 10 participants will be enrolled at up to 3 US sites and treated with TA once weekly via ICV infusion for up to approximately 52 weeks, or until TA becomes commercially available.

Conditions

  • Mucopolysaccharidosis Type IIIB
  • MPS IIIB (Sanfilippo B Syndrome)

Interventions

  • Tralesinidase alfa (TA)Drug

    Tralesinidase alfa (TA) is a sterile solution of recombinant human alpha-N-acetylglucosaminidase fused with insulin-like growth factor 2 (rhNAGLU-IGF2), formulated at 30 mg/mL for ICV infusion. Dose: 200 mg (6.7 mL) for participants age ≥12 to \<24 months; 300 mg (10 mL) for participants age ≥24 months. Administered once weekly via ICV reservoir following isovolumetric removal of up to 10 mL CSF, infused over approximately 10 minutes. Stored frozen at -40°C (±10°C).

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Oakland Research Institution

    Oakland, California · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.